Literature DB >> 8577935

Binding of valsartan to mammalian angiotensin AT1 receptors.

M de Gasparo1, S Whitebread.   

Abstract

The binding characteristics of the angiotensin AT1 receptor antagonist valsartan were investigated in different animal species and tissues. Using [125I](Sar1,Ile8) angiotensin II as radioligand, affinity constants were determined in liver and adrenal rat and marmoset, human adrenal and in rat aortic smooth muscle cells. In all tissues tested, valsartan had a greater affinity for the AT1 receptor than losartan (on average 5-fold). The affinities of both antagonists were up to 30 times weaker in the dog tissues [3H]Valsartan bound with high affinity (Kd 1.44 nmol/l) to the rat aortic smooth muscle cell AT1 receptor. Binding was saturable and reversible. Non-specific binding was low (10%). Reports that [3H]losartan binds to a non-angiotensin II binding site in rat liver and in other tissues could be confirmed. [3H]Valsartan on the other hand bound only to the AT1 receptor. Using a competition binding assay with [3H]losartan on rat liver membranes it could be shown that valsartan can bind to the 'losartan binding site', but at a 10,000-fold less affinity than for the AT1 receptor. Valsartan is therefore a highly specific and selective antagonist of the AT1 receptor. Due to its high affinity and low non-specific binding it is a suitable radioactive antagonist for the study of the distribution and function of the angiotensin AT1 receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8577935     DOI: 10.1016/0167-0115(95)00085-p

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  9 in total

Review 1.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.

Authors:  A Markham; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension.

Authors:  Xin Zhang; Zi-Lun Li; John A Crane; Kyra L Jordan; Aditya S Pawar; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Hypertension       Date:  2014-04-21       Impact factor: 10.190

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Influenza A virus mimetic nanoparticles trigger selective cell uptake.

Authors:  Sara Maslanka Figueroa; Anika Veser; Kathrin Abstiens; Daniel Fleischmann; Sebastian Beck; Achim Goepferich
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

5.  Renin activates PI3K-Akt-eNOS signalling through the angiotensin AT₁ and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii.

Authors:  Wen-Han Cheng; Pei-Jung Lu; Michael Hsiao; Chun-Hui Hsiao; Wen-Yu Ho; Pei-Wen Cheng; Chia-Te Lin; Ling-Zong Hong; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

6.  Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.

Authors:  Shin-ichiro Miura; Atsutoshi Okabe; Yoshino Matsuo; Sadashiva S Karnik; Keijiro Saku
Journal:  Hypertens Res       Date:  2012-10-04       Impact factor: 3.872

Review 7.  Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.

Authors:  Keri Wellington; Diana M Faulds
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  New carboxamide derivatives bearing benzenesulphonamide as a selective COX-II inhibitor: Design, synthesis and structure-activity relationship.

Authors:  David Izuchukwu Ugwu; Uchechukwu Chris Okoro; Hilal Ahmad
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

9.  Biological Activity Evaluation of Some New Benzenesulphonamide Derivatives.

Authors:  Florence Uchenna Eze; Uchechukwu Christopher Okoro; David Izuchukwu Ugwu; Sunday N Okafor
Journal:  Front Chem       Date:  2019-09-18       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.